Pfizer
NEWS
The designation will provide for an expedited pathway for regulatory review of the preventative medication, which could come later this year.
BioNTech Chief Executive Officer Ugur Sahin predicts the company’s vaccine for COVID-19, which is it co-developing with Pfizer, could be ready for regulatory approval by the end of the year, with hundreds of millions of doses available for immediate distribution.
A collective of pharmaceutical companies, including Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, has pledged financial support of approximately $1 billion to support the Antimicrobial Resistance Action Fund.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
Pfizer and BioNTech indicate that this data, along with preclinical data and additional data being generated, will be leveraged to choose a dose level and pick the best vaccine candidate out of the several being evaluated.
Bavencio is an anti-PD-L1 checkpoint inhibitor co-developed by Merck KGaA, Darmstadt, German and Pfizer via EMD Serono, a business unit of the two companies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
JOBS
IN THE PRESS